Tau protein and beta-amyloid 1-42 CSF levels in different phenotypes of Parkinson's disease

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F12%3A33140219" target="_blank" >RIV/61989592:15110/12:33140219 - isvavai.cz</a>
Alternative codes found
RIV/00098892:_____/12:#0000279 RIV/61989592:15210/12:33140219
Result on the web
<a href="http://dx.doi.org/10.1007/s00702-011-0708-4" target="_blank" >http://dx.doi.org/10.1007/s00702-011-0708-4</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/s00702-011-0708-4" target="_blank" >10.1007/s00702-011-0708-4</a>

Result language
angličtina
Original language name
Tau protein and beta-amyloid 1-42 CSF levels in different phenotypes of Parkinson's disease
Original language description
Background and Objective: Parkinson's disease (PD) is neurodegenerative disorder with highly heterogeneous clinical manifestations. This fact has prompted many attempts to divide PD patients into clinical subgroups. This could lead to a better recognition of pathogenesis, improving targeted treatment and the prognosis of PD patients. The aim of the present study was to obtain cerebrospinal fluid (CSF) samples in PD patients and to search for a relationship between neurodegenerative CSF markers (tau protein, beta-amyloid 1-42 and index tau protein/beta-amyloid 1-42) and the clinical subtypes.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FH - Neurology, neuro-surgery, nuero-sciences
OECD FORD branch
—

Project
<a href="/en/project/NT12221" target="_blank" >NT12221: Markers of neurodegeneration in differential diagnosis of parkinsonian syndrome</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year
2012
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)